Bevacizumab (Avastin, Roche), a humanized monoclonal immunoglobulin G1 antibody targeting circulating VEGF, has been shown to improve clinical outcomes in combination with chemotherapy in various cancer types, such as colorectal, lung and ovarian cancers [4–9]. Here, VEGFA is linked to cancer.